Blog
1014 Articles
The FDA Approves Rasonque™ (Daraxonrasib)
The FDA has approved Rasonque (daraxonrasib), the first drug approved to target KRAS in pancreatic cancer patients.
Could AI Help Detect the Pancreatic Cancers We Usually Miss?
Dr. Ajit Goenka is leading a team at the Mayo Clinic that is exploring how AI can be used to find random pancreatic cancer.
The Risk of a Dilated Pancreatic Duct
Dr. Mimi Canto and the team at Johns Hopkins have identified a dilated pancreatic duct as a risk factor for pancreatic cancer.
Daraxonrasib: What To Know About Common Side Effects
Oncodermatologist Dr. Ian Tattersall discusses the rash caused by the new KRAS drug daraxonrasib, and best options to manage the rash.
Tackling KRAS G12D
Dr. Leon Pappas explains the workings of the new KRAS G12D inhibitor, now in phase I/II clinical trials around the US and Australia.
Pancreatic Cancer: The Newest Treatments
Learn more about daraxonrasib and other newest treatments for pancreatic cancer by watching the recording of our webinar.
ASCO 2026: An Update on Research
Daraxonrasib wasn’t the only research news to come out at ASCO 2026. Learn about other new drugs and tests for pancreatic cancer.